Table 2.
Selected clinical trials of antibodies targeting tumor glycans.
| Target | Drug Candidate | Phase | Cancer Type | Status Time Period |
CT ID Refs |
|---|---|---|---|---|---|
| GD2 | |||||
| hu 14.18 (Dinutuximab) | III | High risk Neuroblastoma | Active, not recruiting October 2010–September 2021 |
NCT00026312 [36] | |
| hu3F8 (Naxitamab) + GM-CSF | II | High risk Neuroblastoma | Recruiting 4/2018–11/2027 |
NCT03363373 | |
| hu3F8 + GM-CSF | I/II | High risk Neuroblastoma | Active, not recruiting 12/2012–12/2023 |
NCT01757626 [43,44] |
|
| Naxitamab hu3F8 + GM-CSF + irinotecan and temozolomide |
II | Recurrent Neuroblastoma | Recruiting 11/2021–10/2026 |
NCT04560166 | |
| Dinutuximab hu 14.18 + GM-CSF |
II | Lung cancer Osteosarcoma |
Active, not recruiting 11/2015–10/2021 |
NCT02484443 | |
| hu3F8 + GM-CSF | II | Osteosarcoma | Recruiting 7/2015–7/2022 |
NCT02502786 [45] | |
| hu14.18-IL2 | II | Melanoma | Completed 12/2007–11/2019 |
NCT00590824 [46,47] |
|
| I 131 mAb 3F8 + bevacizumab | I | Neuroblastoma | Completed 8/2006–9/2015 |
NCT00450827 | |
| I 131 mAb 3F8 | I | Central nervous system, Leptomeningeal metastases | Active, not recruiting 1/2006–1/2022 |
NCT00445965 | |
| Hu3F8-Bispecific antibody (GD2-CD3) | I/II | Neuroblastoma Osteosarcoma Solid Tumors |
Recruiting 2/2019–2/2022 |
NCT03860207 [48] | |
| Anti-GD2/CD3 bispecific antibody (Nivatrotamab) | I/II | SCLC | Recruiting 8/2021–12/2024 |
NCT04750239 | |
| GD3 | |||||
| PF-06688992 Anti-GD3/drug conjugated |
I | Stage III/IV Melanoma | Completed 5/2017–1/2020 |
NCT03159117 | |
| Human Chimeric Ab KW2871 (ecromeximab) | I/II | Stage IV Melanoma | Terminated 11/2004–2/2015 |
NCT00199342 [49] |
|
| Human Chimeric Ab KW2871 (ecromeximab) + high dose IFN-α2b | II | Metastatic Melanoma | Completed 3/2008–2/2018 |
NCT00679289 [50] |
|
| fucosyl-GM1 | |||||
| BMS-986012 + platinum + etoposide | I/II | SCLC | Active, not recruiting 11/2016–4/2021 |
NCT02815592 | |
| BMS-986012 | I/II | Relapsed/refractory SCLC | Active, not recruiting 11/2014–6/2022 |
NCT02247349 [51] |
|
| BMS-986012 + carboplatin + etoposide + nivolumab | II | Extensive-stage SCLC | Recruiting 3/2021–9/2024 |
NCT04702880 | |
| Globo H | |||||
| OBI-888 | I/II | Advanced and metastatic solid tumors | Recruiting 5/2018–12/2022 |
NCT03573544 | |
| OBI-999 immunotoxin | I/II | Locally advanced solid tumors | Active, not recruiting 12/2019–12/2023 |
NCT04084366 | |
| Tn antigen | |||||
| Anti- TA-MUC1 (PankoMab-GEX™) | I | Solid tumors | Completed 11/2009–5/2021 |
NCT01222624 [52] |
|
| Anti- TA-MUC1 (PankoMab-GEX™) | II | Recurrent Ovarian cancer, Fallopian cancer, Peritoneal cancer | Completed 9/2013–10/2020 |
NCT01899599 [53] |
|
| Anti- TA-MUC1 (Gatipotuzumab) + anti-EGFR (Tomuzotuximab) | I | Solid tumors | Completed 11/2017–7/2021 |
NCT03360734 [54] |
|
| TF antigen | |||||
| yttrium Y 90-m170 cyclosporine paclitaxel |
I | Breast cancer | Unknown 3/2001–9/2013 |
NCT00009763 [55] |
|
| yttrium Y 90-m170 cyclosporine paclitaxel |
I | Prostate cancer | Unknown 3/2001–9/2013 |
NCT00009750 [55] |
|
| LeA | |||||
| hu mAb-5B1 (MVT-5873) + FOLFIRINOX | 1 | Pancreatic cancer or CA19-9 positive malignancies | Recruiting 1/2016–1/2023 |
NCT02672917 | |
| hu mAb-5B1 (MVT-5873) | 2 | Operable tumors expressing CA19-9 | Recruiting 11/2019–12/2024 |
NCT03801915 [56] | |
| LeY | |||||
| hu3S193 | 1 | SCLC | Completed 2/2004–6/2015 | NCT00084799 [57] | |
| hu3S193 | 2 | Fallopian tube, Ovarian cancer, Primary peritoneal cancer | Completed 5/2008–6/2012 |
NCT00617773 [58] |
|
| SGN-15 + docetaxel | 2 | NSCLC | Completed 1/2003–10/2011 |
NCT00051571 [59] |